August 2, 2018

BETHESDA, MD. August 2, 2018– Brain­Scope today announced its sec­ond con­sec­u­tive nom­i­na­tion for the annu­al Prix Galien USA Awards for “Best Med­ical Tech­nol­o­gy” prod­uct.  Its flag­ship Brain­Scope One prod­uct is a mul­ti-modal, com­pre­hen­sive, hand­held capa­bil­i­ty to help clin­i­cians objec­tive­ly and rapid­ly assess and triage head injured patients direct­ly at the point of care.

BrainScope’s inno­v­a­tive tech­nol­o­gy address­es a vast mar­ket need for the glob­al epi­dem­ic of mild head injury, which impacts more peo­ple each year than stroke and heart fail­ure com­bined. Brain­Scope One is the first FDA-cleared med­ical device to offer capa­bil­i­ties to assess the full spec­trum of brain injury – from con­cus­sions (func­tion­al abnor­mal­i­ty) to brain bleeds (struc­tur­al injury).  Recent white papers authored by third par­ties have shown the poten­tial for Brain­Scope One to decrease unnec­es­sary head CT scans by one-third, to reduce head injury refer­rals to emer­gency depart­ments by up to 75% and to reduce health­care costs for pay­ers and patients by over 30%.

The Prix Galien USA Awards are bestowed by the Galien Foun­da­tion which “…fos­ters, rec­og­nizes and rewards excel­lence in sci­en­tif­ic inno­va­tion to improve the state of human health. It is wide­ly regard­ed as the equiv­a­lent of the Nobel Prize in bio­phar­ma­ceu­ti­cal and med­ical tech­nol­o­gy research.” Nom­i­nees are eval­u­at­ed by a com­mit­tee of twelve esteemed sci­en­tif­ic lead­ers from the bio­phar­ma­ceu­ti­cal indus­try and acad­e­mia, includ­ing four Noble Lau­re­ates.  As one of ten nom­i­nees for “Best Med­ical Tech­nol­o­gy”, Brain­Scope stands among promi­nent med­ical device com­pa­nies such as Abbott, Boston Sci­en­tif­ic and Medtronic.

Brain­Scope CEO Michael Singer stat­ed, “It is a tremen­dous hon­or to be nom­i­nat­ed for the Prix Galien USA award, and to be nom­i­nat­ed twice is a tes­ta­ment to our team’s efforts in cre­at­ing tan­gi­ble sci­en­tif­ic and health impacts with the cre­ation and com­mer­cial­iza­tion of Brain­Scope One. We are grate­ful to the Galien Foun­da­tion for its recog­ni­tion of our inno­va­tion and ded­i­ca­tion to pro­vid­ing the pub­lic with objec­tive and com­pre­hen­sive neu­ro­log­i­cal assess­ment capa­bil­i­ties address­ing the glob­al brain injury problem.”

About Brain­Scope

BrainScope’s mis­sion is to rev­o­lu­tion­ize the rapid and objec­tive assess­ment of brain-relat­ed con­di­tions, start­ing with con­cus­sion and mild trau­mat­ic brain injury, uti­liz­ing mul­ti­ple inte­grat­ed assess­ment capa­bil­i­ties, arti­fi­cial intel­li­gence (AI) and dig­i­ti­za­tion with­in a cul­ture of qual­i­ty, excel­lence and entre­pre­neuri­al­ism.  The Company’s first prod­uct intro­duced in 2017, Brain­Scope One (cleared as Ahead 300), incor­po­rates a mul­ti-modal pan­el of capa­bil­i­ties includ­ing EEG-based tech­nol­o­gy that is non-inva­sive for mild­ly pre­sent­ing head injured patients, 18–85 years old, with­in 3 days after injury and is not a replace­ment to CT scan. BrainScope’s tech­nol­o­gy plat­form inte­grates data­bas­es of thou­sands of brain­wave record­ings with AI tech­nol­o­gy and minia­tur­ized hard­ware and dis­pos­able head­set sen­sors, all of which are cov­ered by an exten­sive intel­lec­tu­al prop­er­ty port­fo­lio of over 100 issued and pend­ing patents glob­al­ly. Brain­Scope has received five FDA clear­ances and ISO 13485:2003 Cer­ti­fi­ca­tion. It has 24 peer-reviewed pub­li­ca­tions on its tech­nol­o­gy. Brain­Scope has part­nered with the U.S. Depart­ment of Defense for the devel­op­ment of its TBI assess­ment tech­nol­o­gy, and Brain­Scope One is cur­rent­ly being field­ed by the U.S. mil­i­tary, both state­side and inter­na­tion­al­ly. Brain­Scope One is also being uti­lized in a cross-sec­tion of mar­ket seg­ments includ­ing: urgent care and occu­pa­tion­al health clin­ics; con­cus­sion clin­ics; hos­pi­tal emer­gency rooms; uni­ver­si­ty sports and stu­dent health cen­ters; pro­fes­sion­al sports; and phar­ma­ceu­ti­cal clin­i­cal tri­als.  Brain­Scope has been the recip­i­ent of sev­er­al pres­ti­gious awards, includ­ing the Frost & Sul­li­van 2017 Best Prac­tices Award for New Prod­uct Inno­va­tion in the Trau­mat­ic Brain Injury Assess­ment Solu­tions Mar­ket, was a two-time win­ner of the GE-NFL Head Health Chal­lenge, and has now received two nom­i­na­tions for the Prix Galien Best Med­ical Tech­nol­o­gy, regard­ed as the equiv­a­lent of the Nobel Prize for med­ical devices. For more infor­ma­tion, please vis­it www​.brain​scope​.com.